TrialSignal
Clinical trial intelligence report
The Effects of Neprilysin on Glucagon-like Peptide-1
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT03717688-Jul 28, 2026
NCT ID
NCT03717688
Status
COMPLETED
Phase
PHASE4
Sponsor
Nicolai Jacob Wewer Albrechtsen
Executive brief
Investment-Ready Snapshot
The Effects of Neprilysin on Glucagon-like Peptide-1 is a PHASE4 clinical asset sponsored by Nicolai Jacob Wewer Albrechtsen in Diabetes, Heart Failure. SEO and diligence focus: Entresto, Sitagliptin 100mg, Placebos, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03717688
Indication
Diabetes
Modality
small molecule
Target
Entresto, Sitagliptin 100mg, Placebos
Intervention
Entresto, Sitagliptin 100mg, Placebos
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.